TMPRSS2 and neoplasm: Inhibitors targeting TMPRSS2 could potentially reduce SARS‐CoV‐2 infectivity; however, their use must be balanced against the risk of promoting tumor progression in cancers where TMPRSS2 acts as a suppressor [87].